The impact of skeletal muscle abnormalities on tolerance to adjuvant chemotherapy and radiation and outcome in patients with endometrial cancer
Authors:
- 8 August 2019
- journal article
- research article
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 64 (1) , 104-112
Abstract
Introduction: Skeletal muscle abnormalities, such as low skeletal muscle mass, measured by skeletal muscle index (SMI), and low skeletal muscle quality, measured by skeletal muscle density (SMD), are associated with poor prognosis in cancer. There has been little investigation of their impact on tolerance to radiation therapy and overall outcome in gynaecologic cancers. We examined the effect of low SMI and SMD on treatment tolerance and survival outcomes in patients with endometrial cancer receiving pelvic radiation.Methods: Stage IB‐IVA patients with endometrial cancer treated at one institution between 2007 and 2017 were reviewed. All patients received hysterectomy and pelvic radiation. SMI was based on the cross‐sectional area of skeletal muscle at the L3 vertebral body. SMD was expressed as the mean radiation attenuation in Hounsfield units (HUs) at the same vertebral level.Results: Sixty‐four patients met criteria for analysis. Forty‐four per cent had low SMI (2/m2), 80% had low SMD (mean < 33 HU if BMI> 25 and mean < 41 HU if BMI < 25), and 33% had both. Patients with both features were less likely to complete planned chemotherapy (p = 0.01); this was consistent on multivariate analysis. Radiation treatments were well‐tolerated regardless of SMI or SMD. On survival analysis, having both low SMI and low SMD was associated with poorer outcomes compared with having either individual factor (p = 0.04).Conclusion: Large percentages of patients with endometrial cancer have low skeletal muscle mass and density. Low skeletal muscle measures predict for poor tolerance to chemotherapy in this patient population. Compliance with adjuvant radiation is high, regardless of SMI and SMD.Keywords
This publication has 28 references indexed in Scilit:
- Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patientsClinical Nutrition, 2016
- Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic reviewEuropean Journal of Cancer, 2016
- Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass IndexJournal of Clinical Oncology, 2013
- Understanding the mechanisms and treatment options in cancer cachexiaNature Reviews Clinical Oncology, 2012
- Obesity and endometrial cancer survival: a systematic reviewInternational Journal of Obesity, 2012
- A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancerGynecologic Oncology, 2009
- Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine TreatmentClinical Cancer Research, 2009
- A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine careApplied Physiology, Nutrition, and Metabolism, 2008
- Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based studyThe Lancet Oncology, 2008
- Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort studyBMJ, 2007